Bachem
  • Products & Services
    • CMC Development
      • Peptide NCEs
      • Oligonucleotide NCEs
    • Commercial API
      • Commercial NCEs
      • Commercial Generics
    • Research & Specialties
      • Catalog Peptides
      • Custom Peptide Synthesis
      • Amino Acid Derivatives
      • Diagnostics
      • Cosmetic Peptides
    • Services & Capabilities
      • Project Management
      • Quality & Regulatory
      • Analytical capabilities
      • GMP Production
      • Research Grade Production
      • Supply & vertical integration
  • About Bachem
    • Company overview
      • Our Purpose
      • Our vision & strategy
      • Our Leadership
      • Our History
      • Our Locations
    • Innovation
      • Innovation matters
      • Innovation collaborations
    • Sustainability
      • People & culture
      • Safeguarding the environment
      • Acting ethically
    • Investors & Media
      • Reports & Presentations
      • Financial events
      • Media Library
      • Press archive
  • News & Events
    • News
    • Events
  • Careers
  • Contact
Select Page
Bachem reports excellent results in 2020 – Sales exceed 400 million CHF for the first time

Bachem reports excellent results in 2020 – Sales exceed 400 million CHF for the first time

Mar 12, 2021 | Ad-hoc, Featured news, Finance, News, Press

Group sales increase by 28.1% to 402.0 million CHF EBITDA margin rises from 27.8% to 30.5% / EBIT margin rises from 19.9% to 24.0% Operating profit (EBIT) increases by 55.0% to 96.7 million CHF Creation of 272 new jobs, 201 of them in Switzerland Despite the...
Knowledge Center
General Conditions
Legal Statement
Privacy Policy
Imprint
Contact
  •  

  •  

  •  

  •  

  •